Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Disc Medicine (IRON – Research Report). The associated price target remains the same with $118.00.
Douglas Tsao has given his Buy rating due to a combination of factors, primarily focusing on the promising prospects of Disc Medicine’s lead product candidate, bitopertin. The company has made significant progress in its discussions with the FDA, achieving alignment on the design for the post-marketing confirmatory Phase 3 study, which is crucial for the accelerated approval process for erythropoietic protoporphyria (EPP). The successful outcomes of the Phase 2 BEACON and AURORA studies, which showed significant reductions in protoporphyrin IX, bolster confidence in bitopertin’s potential approval and subsequent market launch, anticipated in the first half of 2026.
Additionally, Disc Medicine’s advancement in other clinical programs, such as the Phase 2 trial of Disc-0974 for anemia of myelofibrosis, reflects a robust pipeline with promising data. The company’s financial health is also noteworthy, with a strong cash position expected to support operations into 2028, bolstered by recent public offerings. This financial stability, coupled with the potential for bitopertin’s success and the advancement of other pipeline candidates, underpins Tsao’s optimistic outlook and Buy rating for Disc Medicine.
Tsao covers the Healthcare sector, focusing on stocks such as Xenon, Protagonist Therapeutics, and Arcutis Biotherapeutics. According to TipRanks, Tsao has an average return of 9.6% and a 38.99% success rate on recommended stocks.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $85.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com